Alan Thompson
Papers
2
Total Citations
39
H-Index
2
About
Alan Thompson is a leading clinical researcher in radiation oncology, with a primary focus on prostate cancer treatment and comparative effectiveness research. His most impactful work centers on the PACE (Prostate Advances in Comparative Evidence) trial program, which has fundamentally shaped the evidence base for stereotactic body radiotherapy (SBRT) in localized prostate cancer. Thompson’s landmark contribution is the PACE-A trial, an international phase 3 randomized controlled trial that directly compared SBRT to surgery. This study, published in 2023 and already cited 31 times, provided the first high-level randomized evidence on quality-of-life outcomes between these two standard-of-care modalities, addressing a critical gap in therapeutic equipoise. His earlier work on patient acceptance of randomization within the PACE study (8 citations) demonstrated the feasibility of conducting such rigorous trials in a sensitive clinical setting. By generating level 1 evidence for SBRT, Thompson has empowered clinicians and patients to make more informed, shared decisions, and his research continues to influence international treatment guidelines for early-stage prostate cancer.
Research Focus
Key Achievements
Top Papers
- 1
- 2